1	SUBMITTED 1 MAR 24
2	REVISION REQ. 17 APR 24; REVISION RECD. 3 MAY 24
3	ACCEPTED 29 MAY 24
4	ONLINE-FIRST: JUNE 2024
5	DOI: https://doi.org/10.18295/squmj.6.2024.041
6	
7	Schwannoma of the Appendix Mimicking a Metastatic Breast Cancer
8	A case report
9	*Zaid Al-Ishaq,¹ Alonood Al-Sulaimani,² Badriya S. Al-Qassabi,³ Fathiya
LO	AlRahbi, ⁴ Khalid Al Baimani, ⁵ Jawa Z. Muhammad, ⁶ Adil Aljarrah ¹
l1	
L2	Departments of ¹ Surgical Oncology, ³ Radiology and ⁵ Medical Oncology, Sultan Qaboos
L3	Comprehensive Cancer Care and Research Centre, University Medical City, Muscat, Oman;
L4	Departments of ² Surgery, ⁴ Pathology and ⁶ Radiology & Molecular Imaging, Sultan Qaboos
L5	University Hospital, University Medical City, Muscat, Oman
L6	*Corresponding Author's e-mail: mr.zaidraouf@gmail.com
L7	
L8	Abstract
L9	Metastatic breast cancer (MBC) represents 5-10% of newly diagnosed breast cancer cases,
20	referred to as de novo stage IV MBC. Distinguishing a distant lesion in breast cancer patients
21	can be challenging. Therefore, obtaining a histopathological confirmation of a metastasis is
22	advisable, as a suspicious metastatic lesion may turn out to be benign or exhibit different
23	immunohistochemistry compared to the primary site. In this case, we describe a woman
24	undergoing staging scans for newly diagnosed breast cancer, where radiological findings
25	suggested appendix metastasis. However, subsequent laparoscopic appendicectomy revealed
26	an appendicular schwannoma, confirmed through immunohistochemistry. The patient then
27	received curative-intent breast cancer treatment. With the increasing use of advanced staging

scans in breast cancer, clinicians should thoroughly investigate and confirm metastatic 28 disease, especially in uncommon metastatic sites, before initiating treatment. 29 **Keywords:** Schwannoma, metastasis, breast cancer, appendix. 30 31 Introduction 32 Metastatic breast cancer (MBC), also known as de novo stage IV MBC, represents 5-10% of 33 newly diagnosed breast cancer (BC) cases in Western countries and 13% in Oman. 1,2 34 Gastrointestinal (GI) tract metastases from BC are infrequent, reported in autopsy series with 35 varying incidence (8-35%).³ Distinguishing distant lesions in breast cancer patients can be 36 challenging,⁴ impacting treatment decisions reliant on disease stage.⁵ Hence, 37 histopathological confirmation is advisable as suspicious metastatic lesions may prove benign 38 or exhibit different immunohistochemistry compared to the primary site. ⁶ This case report 39 describes an appendicular schwannoma mimicking metastatic breast cancer. Schwannomas 40 are the most common type of peripheral nerve tumors and can rarely affect the GI system, 41 often being diagnosed incidentally. Diagnosis is confirmed through histopathology and 42 immunohistochemistry. Total surgical excision is the recommended treatment for GI 43 44 schwannoma. 45 **Case Report:** 46 A 55-year-old woman presented at a one-stop breast clinic with a one-month history of a left 47 breast lump, with no other symptoms. The patient had a medical history of type 2 diabetes 48 49 mellitus and hypertension, managed with regular medication, with no relevant family history. On examination, a 3 cm ill-defined, hard, mobile lump was noted in the upper outer quadrant 50 of the left breast. Breast Ultrasonography revealed an irregular hypoechoic lesion measuring 51 52 2.9 x 1.7 cm in the left breast at 3 o'clock position, with microcalcifications within. Left axillary ultrasound indicated a suspicious lymph node measuring 6.6 mm. Mammogram 53 showed asymmetric density in the left breast classified as BIRADS 5. True cut biopsy 54 confirmed invasive Ductal carcinoma (IDC) with negative estrogen and progesterone 55 receptors, positive HER2, and a Ki67 of 45%. Fine needle aspiration cytology from the left 56 axillary lymph node was negative for metastasis. 57 58 During staging workup, Contrast-enhanced Computed Tomography (CE-CT) scans revealed 59 two subserosal nodules in the appendix (figure 1. A-C) and prominent mesenteric lymph 60 nodes in the right iliac fossa (figure 1. C). A Positron Emission Tomography scan (PET) 61

indicated a hypermetabolic left breast mass (SUV max 17.8) (figure 2. A&B) and suspicious 62 metastatic lesion in the appendix (SUV max 21.5) (figure 2. C-D). 63 64 In a Multidisciplinary Meeting, consensus favored evaluating the appendicular lesion before 65 initiating breast cancer treatment. Diagnostic colonoscopy showed no abnormality. 66 Subsequently, the patient underwent laparoscopic appendectomy to determine the exact 67 nature of the appendicular lesion. 68 69 Pathological examination revealed a well-demarcated tumor at the appendix tip, composed of 70 spindle-shaped cells proliferating in a bundle from the muscularis externa (figure 3.a). The 71 72 tumor displayed classic schwannoma features, including spindle cell morphology, nuclear palisading, and Verocay bodies (figure 3.b). Vascular invasion and lymph duct invasion were 73 absent. Immunohistochemical studies confirmed S-100 protein positivity (figure 3.c) and 74 negativity for CD117, DOG-1, CD34, SMA, Desmin, AE1/3, CAM5.2, B-Catenin, ALK-1, 75 c-KIT and CD34(figure 3.d), confirming the appendicular schwannoma diagnosis. 76 77 Following the exclusion of metastatic disease, the patient commenced neoadjuvant 78 chemotherapy based on anthracycline, taxane and dual Her2 blockades. Subsequent left 79 breast image-guided wide local excision and sentinel lymph node biopsy revealed a 80 81 pathological complete response (pCR). Adjuvant radiotherapy and 18 cycles of trastuzumab every 3 weeks were administered. The patient also received Alendronate and Calcium with 82 83 Vitamin D for osteopenia, alongside regular medications. It's worth noting that the patient underwent comprehensive panel of gene testing, including NF1 and NF2, but no responsible 84 85 gene was detected. The patient consent was obtained for publication purposes. 86 87 Discussion: Metastatic breast cancer (MBC) represents 5-10% of newly diagnosed cases, referred to as de 88 novo stage IV MBC. GI tract metastases from BC are rare, occurring in 8-35% of cases. 89 Identifying distant lesions during staging scans in newly diagnosed breast cancer patients 90 91 presents challenges, ascertaining whether these lesions represent distant metastases or primary lesions within the organ. 92 93 In our case, a staging contrast enhanced computed tomography (CE-CT) scan revealed an 94 appendicular lesion confirmed as suspicious for metastasis on PET scan. However, 95

differential diagnoses include gastrointestinal stromal tumors (GISTs) and solitary 96 neuroendocrine tumors. Occasionally, lymphomas and GI adenocarcinomas may mimic 97 mesenchymal tumors.⁷ 98 99 Fluorodeoxyglucose (FDG)-positron emission tomography is effective in detecting malignant 100 tumors. However, FDG accumulation has been noted in schwannomas, 8 making it 101 challenging to differentiate them from distant metastases through imaging alone. 102 Furthermore, the discordance rates in biomarkers between primary tumors and metastatic 103 disease emphasize the importance of histopathological assessment. Studies have reported 104 hormone receptor discordance rates ranging from 30% to 40% and HER-2/neu discordance 105 rates ranging from 10% to 30%. These findings highlight the importance of histopathological 106 confirmation of suspicious appendicular lesions before starting treatment. This approach led 107 to the consideration of laparoscopic appendectomy, resulting in the diagnosis of appendicular 108 schwannoma., and the breast cancer was treated with curative intent. 109 110 Schwannoma is a rare mesenchymal tumor affecting the gastrointestinal tract, primarily 111 observed in the stomach and often diagnosed incidentally. ¹⁰ Appendiceal schwannoma, an 112 exceptionally rare variant, has been documented in only 15 reported cases in the existing 113 literature, and definitive characteristic findings are yet to be established. 11 Clinical 114 presentations vary, ranging from asymptomatic cases to appendicitis-like abdominal pain. 115 Notably, perforation is an exceedingly rare occurrence. 12 116 117 On histology, schwannomas are typically composed of spindle cells that stain strongly 118 positive for S100 and focally for GFAP and CD57 on Immunohistochemistry. These findings 119 are sufficient to confirm the diagnosis in the absence of KIT positivity and smooth muscle 120 markers. 10 While schwannoma and on GIST have similar histological findings in that they 121 both demonstrate a spindle-like proliferation, they have distinct immunohistochemistry 122 staining. Greater than 95% of GISTs express c-Kit (CD117), CD34 (70%), and H-caldesmon 123 (80%).¹⁰ 124 125 Levy et al. described the radiological features of histopathologically proven schwannomas as 126 well-defined homogeneously attenuating mural masses on CT. They lack the poor prognostic 127 factors seen typically in gastrointestinal stromal tumors such as low attenuating haemorrhage, 128 necrosis, or degradation within the tumor. 13 Furthermore, Suzuki et al highlighted the 129

130	radiological findings of peritumoral lymph node swelling as a potential differentiator for
131	Schwannoma compared to other appendicular tumors, serving as a valuable diagnostic clue.
132	This lymphadenopathy may be linked to cytokine release from tumor cells, inducing
133	chemokinesis of lymphocytes. 14 Coincidentally, our radiological findings align with known
134	patterns as described by Suzuki et al. Nonetheless, additional research on the diagnostic
135	characteristics of schwannoma is warranted.
136	
137	For confirmed gastrointestinal schwannomas, complete surgical excision is the recommended
138	approach, while partial excision may be considered for large tumors posing a risk of nerve
139	damage. It is noteworthy that even with partial excision, the occurrence of malignant
140	transformation remains extremely rare. ¹⁰
141	
142	Conclusion
143	Our case highlights the importance of maintaining a broad spectrum of differential diagnoses
144	and obtaining histopathological confirmation when identifying lesions during staging scans in
145	patients with breast cancer. This approach not only confirms the diagnosis but also ascertain
146	immunophenotypes to enable the selection of the most suitable subsequent therapy.
147	
148	Author Contributions
149	ZA, AA-S, BSA, FA and JZM contributed to writing the initial draft of the manuscript and
150	critical review. KAB and AA contributed to the critical review All authors approved the final
151	version of the manuscript.
152	
153	Reference:
154	1. Barcenas CH, Song J, Murthy RK, Raghavendra AS, Li Y, Hsu L, et al. Prognostic
155	Model for De Novo and Recurrent Metastatic Breast Cancer. JCO Clin Cancer
156	Inform. 2021 Aug; 5:789-804. doi: 10.1200/CCI.21.00020.
157	2. Ministry of Health, Sultanate of Oman. Oman Cancer Incidence Report 2020.
158	[Online]. Pp 48. Accessed on: [02-05-2024].
159	3. Di Micco R, Santurro L, Gasparri ML, Zuber V, Fiacco E, Gazzetta G, Smart CE,
160	Valentini A, Gentilini OD. Rare sites of breast cancer metastasis: a review. Transl
161	Cancer Res. 2019 Oct;8(Suppl 5): S518-S552. doi: 10.21037/tcr.2019.07.24.

- 4. Paek SH, Woo J, Woo KJ, Kim KC, Lim W. Pleural Schwannoma Suspected as
- Metastasis of Breast Cancer. Am J Case Rep. 2020 Mar 26;21: e921548. doi:
- 164 10.12659/AJCR.921548.
- 5. Trayes KP, Cokenakes SEH. Breast Cancer Treatment. Am Fam Physician. 2021 Aug
- 166 1;104(2):171-178
- 6. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does
- 168 confirmatory tumor biopsy alter the management of breast cancer patients with distant
- metastases? Ann Oncol. 2009 Sep;20(9):1499-1504. doi: 10.1093/annonc/mdp028.
- 7. Kang HC, Menias CO, Gaballah AH, Shroff S, Taggart MW, Garg N, et al. Beyond
- the GIST: mesenchymal tumors of the stomach. Radiographics. 2013 Oct;33(6):1673-
- 90. doi: 10.1148/rg.336135507.
- 8. Kumagai H, Takehana K, Shioi Y, Tono C. Axillary schwannoma mimicking lymph
- node metastasis-associated breast cancer: a case report. Surg Case Rep. 2022 Jul
- 175 18;8(1):135. doi: 10.1186/s40792-022-01493-8.
- 9. Lower EE, Khan S, Kennedy D, Baughman RP. Discordance of the estrogen receptor
- and HER-2/neu in breast cancer from primary lesion to first and second metastatic
- site. Breast Cancer (Dove Med Press). 2017 Aug 2; 9:515-520. doi:
- 179 10.2147/BCTT.S137709.
- 180 10. Alkhattab M, Dhannoon A, Sehgal R, Gormley C, Sheehan M, Mclaughlin R.
- Schwannoma of the Appendix Orifice. Case Rep Pathol. 2021 Dec 11; 2021:7250145.
- doi: 10.1155/2021/7250145.
- 11. Doyle JP, Bhogal RH, Terlizzo M, Mavroeidis VK. Appendiceal schwannoma -
- report of a case and literature review. Ir J Med Sci. 2023 Aug;192(4):1801-1805. doi:
- 185 10.1007/s11845-022-03184-7
- 12. Hendriks T, Ballal H, McCallum DD. Appendiceal schwannoma: a rare cause of
- perforated appendicitis. BMJ Case Rep. 2018 Aug 4;2018: bcr2018226065. doi:
- 188 10.1136/bcr-2018-226065.
- 13. Levy AD, Quiles AM, Miettinen M, Sobin LH. Gastrointestinal schwannomas: CT
- features with clinicopathologic correlation. AJR Am J Roentgenol. 2005
- 191 Mar;184(3):797-802. doi: 10.2214/ajr.184.3.01840797
- 192 14. Suzuki K, Saito K, Yamada T, Arizono E, Kumita H, Kasahara K, et al. Perilesional
- Lymph Node Swelling Might be a Radiologic Clue for Appendiceal Schwannoma: A




Figure 1 (A-C): Selected contract enhanced CT images of the abdomen showing contract filled appendix with two eccentric nodular wall thickening. The thick blue arrow is pointing to the largest one. There are prominent adjacent regional mesenteric lymph nodes (blue stars).




Figure 2: FDG-18 PET-CT scan, showing the primary left breast cancer (A & B), SUVmax 17.8 (white arrow) with an FDG avid left appendix mass (C & D), SUVmax 21.5 (blue arrow).




Figure 3 (A-D): Pathological findings in Hemotoxylin and Eosin staining showing spindle-shaped heterotypic cells proliferating in a bundle (**A**). Tumor showed features of a schwannoma including spindle cell morphology, nuclear palisading and Verocay bodies (**B**). In immunohistochemical studies, tumor cells were diffusely positive S-100 protein (**C**) and were negative for CD117 (**D**).